The Medicines and Healthcare products Regulatory Agency has joined a new international statement calling for non-animal methods to be advanced across the full lifecycle of human medicines. The statement, adopted through the International Coalition of Medicines Regulatory Authorities, sets a long-term objective of replacing animal testing wherever scientifically robust alternatives are available. For UK medicines regulation, this matters less as an immediate rule change than as a clear statement of regulatory intent. The MHRA is aligning with other authorities behind a common expectation that developers should use non-animal evidence where it can meet the required scientific standard.
According to the ICMRA statement, the ambition extends from early screening and research through non-clinical development, licensing and post-authorisation activity. The breadth is notable because animal testing can be built into several different stages of a product's development and oversight, not just the point immediately before approval. The statement was developed by the European Medicines Agency, the MHRA, the Irish Health Products Regulatory Authority and Swissmedic before being adopted by the wider ICMRA plenary. That gives the document weight beyond a single national regulator and suggests a more coordinated approach to evidence requirements across multiple jurisdictions.
For new medicines, ICMRA is calling on developers to use methods that do not involve animals where those methods are acceptable in a regulatory context and maintain scientific quality. It is also asking regulators to support that shift as far as possible, which places responsibility on both sides of the approval process. In practical terms, that means companies will need to think more carefully about how they build evidence packages using New Approach Methodologies, often referred to as NAMs. The policy message is not that any non-animal data will be sufficient, but that validated non-animal evidence should be used where it can answer the regulatory question reliably.
ICMRA gives particular emphasis to batch release testing, which covers the checks carried out on production batches before supply. The coalition says the greatest reduction in animal use is likely to come at this stage, and it wants regulators to encourage non-animal tests, challenge proposals that rely on animals, and review existing batch release requirements where appropriate. That focus is important because batch release sits within routine manufacturing rather than one-off product development. If non-animal methods become standard here, the effect would be operational as well as scientific, changing quality control expectations for manufacturers and laboratories working across the medicines supply chain.
The MHRA has already begun setting out how this approach should work in the UK. In earlier guidance on medicines using non-animal methods, the agency said it would help developers understand what is required when applications rely on data generated without animal testing, and it has offered early review of such evidence to reduce uncertainty before a marketing authorisation application is submitted. For sponsors, that means regulatory planning may need to start earlier. Validation work, method selection and advance engagement with the regulator are likely to matter just as much as the underlying technology being proposed.
The agency has also said its scientists are researching alternatives including organ-on-a-chip systems, AI-driven predictive models and 3D bioprinted tissues. These tools are often presented as ways to generate more human-relevant data, but the MHRA's position remains cautious on evidential standards. According to the agency, patient access to safe and effective medicines remains the priority, and alternative methods will only be relied on in assessment once they are established as reliable. That is the central qualification in the announcement: acceleration is being encouraged, but the safety threshold is not being lowered.
The latest statement sits within a wider UK policy programme. In March 2026, the MHRA announced further action to support the phase-out of animal testing after the Government published Replacing animals in science: A strategy to support the development, validation and uptake of alternative methods. For developers, manufacturers and researchers, the immediate effect is a clearer policy direction rather than an instant prohibition on animal studies. Organisations preparing medicines submissions or batch control plans can expect closer scrutiny of why animal tests remain necessary, while patients should read the change as an attempt to modernise evidence generation without weakening regulatory safeguards.